Jiuzhitang Maker's third new drug has received implicit approval (Acceptance No.: CXSL2400859) from the National Medical Products Administration for its Investigational New Drug (IND) application, with the intended indication being Autism Spectrum Disorder (ASD).


2025-03-11

Jiuzhitang Maker's third new drug has received implicit approval (Acceptance No.: CXSL2400859) from the National Medical Products Administration for its Investigational New Drug (IND) application, with autism spectrum disorder (ASD) as the targeted indication.

Previous: